Thermo Fisher Scientific Inc (TMO)

Operating profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	7,332,000	7,170,000	7,196,000	7,016,000	6,859,000	6,866,000	6,712,000	7,135,000	8,393,000	9,070,000	9,638,000	9,800,000	10,028,000	10,561,000	10,709,000	9,937,000	7,794,000	5,955,000	4,475,000	4,580,000
Revenue (ttm)	US$ in thousands	42,879,000	42,370,000	42,346,000	42,492,000	42,857,000	43,421,000	43,524,000	43,807,000	44,915,000	44,167,000	42,820,000	41,123,000	39,211,000	39,059,000	38,250,000	35,894,000	32,218,000	28,497,000	26,248,000	25,647,000
Operating profit margin		17.10%	16.92%	16.99%	16.51%	16.00%	15.81%	15.42%	16.29%	18.69%	20.54%	22.51%	23.83%	25.57%	27.04%	28.00%	27.68%	24.19%	20.90%	17.05%	17.86%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $7,332,000K ÷ $42,879,000K
= 17.10%

Thermo Fisher Scientific Inc's operating profit margin fluctuated over the analyzed period from March 31, 2020, to December 31, 2024. The operating profit margin started at 17.86% in March 2020, decreased slightly to 17.05% by June 2020, and then showed a significant improvement to reach 20.90% by September 2020. The margin continued to rise steadily to a peak of 28.00% in June 2021, indicating strong operational efficiency.

Subsequently, there was a slight decline in the operating profit margin from June 2021 to September 2022, with the margin hovering around the range of 20% to 27%. This stability was followed by a gradual decrease in the operating profit margin starting in December 2022 through December 2024, where the margin decreased from 18.69% to 17.10%.

Overall, Thermo Fisher Scientific Inc's operating profit margin exhibited fluctuations but generally demonstrated a strong performance, maintaining levels above 15% throughout the period, which is considered healthy for a company in the industry. Analysts may want to monitor the trend in future periods to assess the company's ability to maintain profitability amidst changing market conditions.